Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/79526
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Vincristine chemotherapy trials and pharmacokinetics in Tasmanian devils with Tasmanian devil facial tumor disease
Author: Phalen, D.
Frimberger, A.
Pyecroft, S.
Peck, S.
Harmsen, C.
Lola, S.
de Mello Mattos, B.
Li, K.
McLachlan, A.
Moore, A.
Citation: PLoS One, 2013; 8(6):1-7
Publisher: Public Library of Science
Issue Date: 2013
ISSN: 1932-6203
1932-6203
Statement of
Responsibility: 
David N. Phalen, Angela Frimberger, Stephen Pyecroft, Sarah Peck, Colette Harmsen, Suzanneth Lola, Beatriz de Mello Mattos, Kong M. Li, Andrew J. McLachlan and Antony Moore
Abstract: Tasmanian Devil Facial Tumor Disease (DFTD) is a transmissible cancer threatening to cause the extinction of Tasmanian Devils in the wild. The aim of this study was to determine the susceptibility of the DFTD to vincristine. Escalating dosage rates of vincristine (0.05 to 0.136 mg/kg) were given to Tasmanian devils in the early stages of DFTD (n = 8). None of these dosage rates impacted the outcome of the disease. A dosage rate of 0.105 mg/kg, a rate significantly higher than that given in humans or domestic animals, was found to the highest dosage rate that could be administered safely. Signs of toxicity included anorexia, vomiting, diarrhea and neutropenia. Pharmacokinetic studies showed that, as with other species, there was a rapid drop in blood concentration following a rapid intravenous infusion with a high volume of distribution (1.96 L/ kg) and a relatively long elimination half life (11 h). Plasma clearance (1.8 ml/min/kg) was slower in the Tasmanian devil than in humans, suggesting that pharmacodynamics and not pharmacokinetics explain the Tasmanian devil’s ability to tolerate high dosage rates of vincristine. While providing base-line data for the use of vincristine in Tasmanian devils and possibly other marsupials with vincristine susceptible cancers, these findings strongly suggest that vincristine will not be effective in the treatment of DFTD.
Keywords: Animals; Marsupialia; Facial Neoplasms; Neutropenia; Anorexia; Diarrhea; Vomiting; Vincristine; Antineoplastic Agents, Phytogenic; Treatment Failure; Injections, Intravenous; Drug Administration Schedule; Half-Life; Australia; Drug Dosage Calculations
Description: Extent: 7 p.
Rights: Copyright: © 2013 Phalen et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
RMID: 0020130400
DOI: 10.1371/journal.pone.0065133
Appears in Collections:Animal and Veterinary Sciences publications

Files in This Item:
File Description SizeFormat 
hdl_79526.pdfPublished version273.92 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.